Acquisition by Lance Alstodt of 100 shares of BioRestorative Therapies at 3.087 subject to Rule 16b-3
| BRTX Stock | USD 1.46 0.01 0.68% |
Slightly above 61% of BioRestorative Therapies' investor base is looking to short. The analysis of the overall investor sentiment regarding BioRestorative Therapies suggests that many traders are alarmed. BioRestorative Therapies' investing sentiment can be driven by a variety of factors including economic data, BioRestorative Therapies' earnings reports, geopolitical events, and overall market trends.
BioRestorative |
Filed transaction by BioRestorative Therapies Officer: President, Ceo, Cob. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at finance.yahoo.com
 |
BioRestorative Therapies Fundamental Analysis
We analyze BioRestorative Therapies' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioRestorative Therapies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioRestorative Therapies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
BioRestorative Therapies is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
BioRestorative Therapies Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioRestorative Therapies stock to make a market-neutral strategy. Peer analysis of BioRestorative Therapies could also be used in its relative valuation, which is a method of valuing BioRestorative Therapies by comparing valuation metrics with similar companies.
Peers
BioRestorative Therapies Related Equities
| CADL | Candel Therapeutics | 26.45 | ||||
| MNPR | Monopar Therapeutics | 6.08 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
| CAPR | Capricor Therapeutics | 0.70 | ||||
| CANF | Can Fite | 0.62 | ||||
| XTLB | XTL Biopharmaceutica | 0.56 | ||||
| SLNO | Soleno Therapeutics | 0.38 | ||||
| CING | Cingulate | 1.40 | ||||
| PULM | Pulmatrix | 1.86 | ||||
| ACHV | Achieve Life | 2.36 | ||||
| BPTH | Bio Path | 2.78 | ||||
| AKTX | Akari Therapeutics | 3.06 | ||||
| CVKD | Cadrenal Therapeutics, | 7.57 | ||||
| SABS | SAB Biotherapeutics | 9.41 |
Additional Tools for BioRestorative Stock Analysis
When running BioRestorative Therapies' price analysis, check to measure BioRestorative Therapies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioRestorative Therapies is operating at the current time. Most of BioRestorative Therapies' value examination focuses on studying past and present price action to predict the probability of BioRestorative Therapies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioRestorative Therapies' price. Additionally, you may evaluate how the addition of BioRestorative Therapies to your portfolios can decrease your overall portfolio volatility.